Policy Notices

• Temporary Extension of Eligibility for the NIH K99/R00 Pathway to Independence Award During the COVID-19 Pandemic
  (NOT-OD-20-158)
  National Institutes of Health
  

• Extending the Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy During the COVID-19 Pandemic
  (NOT-OD-20-163)
  National Institutes of Health
  

General Notices

• Notice of Early Expiration of NOT-AI-20-051 Notice of Special Interest (NOSI): Select Research Areas for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)
  (NOT-AI-20-066)
  National Institute of Allergy and Infectious Diseases
  

• Notice to Extend Eligibility for Submission to PAR-19-371, NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed) due to COVID-related Disruptions
  (NOT-AI-20-067)
  National Institute of Allergy and Infectious Diseases
  

• Temporary Extension of Applicant Eligibility in PAR-19-343 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 - Independent Clinical Trial Not Allowed)"
  (NOT-GM-20-051)
  National Institute of General Medical Sciences
  

• Notice to Encourage Eligible NINDS Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD) Awardees to Apply for PA-20-222 "Research Supplements to Promote Diversity in Health-Related Research"
  (NOT-NS-20-089)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Technical Assistance Webinar for Two NIH Multimorbidity FOAs - PAR-20-179 and PAR-20-180
  (NOT-OD-20-160)
  Office of Disease Prevention
  

• Notice Regarding Revision and New Applications under PAR-15-352: Occupational Safety and Health Training Project Grants (T03)
  (NOT-OH-20-006)
  National Institute for Occupational Safety and Health
  

• Notice Regarding New ERC Applications for PAR-15-303: Occupational Safety and Health Education and Research Centers (T42)
  (NOT-OH-20-007)
  National Institute for Occupational Safety and Health
  

• Request for Information (RFI): Inviting Comments and Suggestions on University-Based Approaches for COVID-19 Surveillance Testing to Review the Current Landscape
  (NOT-OD-20-162)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice of Change to RFA-DA-21-005 "Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)"
  (NOT-DA-21-056)
  National Institute on Drug Abuse
  

• NHLBI confirms participation in NOT-OD-20-119, NOT-OD-20-120, and NOT-OD-20-121 (Research on COVID-19 Testing among Underserved and/or Vulnerable Populations)
  (NOT-HL-20-806)
  National Heart, Lung, and Blood Institute
  

• Notice of Correction to "PAR-20-235, Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans Required)"
  (NOT-MH-20-072)
  National Institute of Mental Health
  

• Notice of Change to Key Dates for PAR-18-528 "NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)"
  (NOT-NS-20-084)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for PAR-18-628 "NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)"
  (NOT-NS-20-090)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change: Late Application Policy for September 28, 2020, Application Due Date for RFA-NS-21-001 "NINDS Morris K. Udall Centers of Excellence for Parkinson's Disease Research (P50 Clinical Trial Optional)"
  (NOT-NS-20-097)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change: Late Application Policy for September 28, 2020, Application Due Date for RFA-NS-21-002 "NINDS Exploratory Grant Program in Parkinson's Disease Research (P20- Clinical Trial Optional)"
  (NOT-NS-20-098)
  National Institute of Neurological Disorders and Stroke
  

• Notice of Change to Key Dates for PAR-18-563 "NIH StrokeNet Small Business Innovation Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (U44 - Clinical Trial Optional)"
  (NOT-NS-20-099)
  National Institute of Neurological Disorders and Stroke
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed)
  (NOT-MH-20-074)
  National Institute of Mental Health
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed)
  (NOT-MH-20-075)
  National Institute of Mental Health
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  

Notices of Special Interest

• Notice of Special Interest: Secondary Analyses of Existing Alcohol Research Data
  (NOT-AA-20-018)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
  (NOT-AI-20-065)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities
  (NOT-MD-20-025)
  National Institute on Minority Health and Health Disparities
  National Cancer Institute
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Mental Health
  National Library of Medicine
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  

• Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations
  (NOT-MD-20-026)
  National Institute on Minority Health and Health Disparities
  

Funding Opportunities

• NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed)
  (PAR-20-259)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): November 2, 2020; October 14, 2021; October 14, 2022
  
  

• Cellular and Molecular Biology of Complex Brain Disorders (R01 Clinical Trial Not Allowed)
  (PAR-20-263)
  National Institute of Mental Health
  Application Receipt Date(s): Standard dates apply The first standard application due date for this FOA is October 5, 2020.
  
  

• Cellular and Molecular Biology of Complex Brain Disorders (R21 Clinical Trial Not Allowed)
  (PAR-20-264)
  National Institute of Mental Health
  Application Receipt Date(s): Standard dates apply. The first standard application due date for this FOA is October 16, 2020.
  
  

• Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)
  (PAR-20-284)
  National Cancer Institute
  Application Receipt Date(s): November 4, 2020, May 6, 2021, November 4, 2021, May 5, 2021, November 3, 3022, May 4, 2023
  
  

• Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Required)
  (RFA-AG-21-021)
  National Institute on Aging
  Application Receipt Date(s): February 3, 2021, October 22, 2021, and October 21, 2022, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date. No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Limited Competition: Childhood Cancer Survivor Study (U24 Clinical Trial Required)
  (RFA-CA-20-052)
  National Cancer Institute
  Application Receipt Date(s): November 18, 2020 No late applications will be accepted for this FOA.
  
  

• Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)
  (RFA-DK-20-003)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): December 1, 2020. No late applications will be accepted for this Funding Opportunity Announcement
  
  

• Liver Cirrhosis Network: Scientific and Data Coordination Center (U24 Clinical Trial Optional)
  (RFA-DK-20-004)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): December 1, 2020. No late applications will be accepted for this Funding Opportunity Announcement All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Mechanisms of Selective Vulnerability in LBD and FTD (R01 Clinical Trial Not Allowed)
  (RFA-NS-21-007)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): October 27, 2020
  
  

• Exploratory/Developmental Grants Related to the World Trade Center Health Program (R21)
  (RFA-OH-21-004)
  National Institute for Occupational Safety and Health
  National Institute on Aging
  Application Receipt Date(s): December 8, 2020 On-time submission requires that electronic applications be error-free and made available to CDC for processing from eRA Commons on or before the deadline date. Applications must be submitted to and validated successfully by Grants.gov/eRA Commons no later than 5:00 PM Eastern Time on the listed application due date. Applicant organizations are strongly encouraged to start the registration process at least 4 weeks prior to the application due date Note: HHS/CDC grant submission procedures do not provide a period of time beyond the application due date to correct any error or warning notices of noncompliance with application instructions that are identified by Grants.gov or eRA systems (i.e., error correction window).